ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

  • 1
  • 2
  • 3
  • …
  • 212
  • Next Page »
Search Again »
  • Abstract Number: 0534 • ACR Convergence 2024

    Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis

    Alexandre Matar1, Maya Breitman2, Tracey Bonfield3, Maricela Haghiac4, Jane Reese3, Emma Barnboym5, Steven Lewis6, Hillard Lazarus7 and Nora Singer8, 1MetroHealth, Westlake, OH, 2MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, 3Case Western Reserve University, Cleveland, OH, 4Metrohealth Medical Center, Cleveland, OH, 5The MetroHealth System, Cleveland, OH, 6Case Western University, MetroHealth, Cleveland, OH, 7Case Western Reserve University/University Hospitals, Cleveland, OH, 8MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Mesenchymal stem (stromal) cells (MSCs) constitute an emerging therapeutic strategy for several human diseases. Small non-randomized studies have shown that MSCs may be a…
  • Abstract Number: 0548 • ACR Convergence 2024

    Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis

    David Kiefer1, Juergen Braun2, Uta Kiltz3, Niklas Kolle1, Lucia Schneider1, Ioana Andreica4, Bjoern Buehring5, Philipp Sewerin6, Imke Redeker7, Styliani Tsiami8, Susanne Herbold9 and Xenofon Baraliakos8, 1Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 5Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, 6Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, 7Ruhr Universität Bochum, Bochum, Germany, 8Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 9Rheumazentrum Ruhrgebiet, Herne, Herne, Germany

    Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…
  • Abstract Number: 0730 • ACR Convergence 2024

    Assessment of the Quality of Life in a Single-center Cohort of Patients with ANCA-Associated Vasculitis on Targeted Therapy: Characterization of Global, Disease and Organ-specific Parameters Using Patient Reported Outcomes

    Michele Moretti1, Elena Elefante2, Francesco Ferro3, Ludovica Pisapia4, Federica Di Cianni5, Nazzareno Italiano6, ROSARIA TALARICO5, Chiara Baldini7 and Marta Mosca7, 1University of Pisa, Pisa, Pisa, Italy, 2Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Pisa, Italy, 3Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 4Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 5University of Pisa, Pisa, Italy, 6University of Pisa, Rovigo, Italy, 7University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy

    Background/Purpose: ANCA-associated vasculitides (AAVs) are characterized by severe and multisystemic manifestations that greatly affect patients' quality of life (QoL). The purpose of the study was…
  • Abstract Number: 0845 • ACR Convergence 2024

    Weight Loss, Disease Activity, and Patient Reported Outcomes in Patients with Musculoskeletal and Autoimmune Diseases Taking Weight Loss Therapies

    Thomas Riley1, Kristin Wipfler2, Katherine Wysham3, Michael George4, Kaleb Michaud5 and Joshua Baker4, 1Hopsital of the University of Pennsylvania, Philadelphia, PA, 2FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Pennsylvania, Philadelphia, PA, 5University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: With the popularity of medication-assisted weight loss, the current study seeks to characterize the association of weight loss, disease activity, and patient reported outcomes…
  • Abstract Number: 1238 • ACR Convergence 2024

    Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in Those with Polymyalgia Rheumatica

    Patricia Harkins1, Sharon Cowley2, seoidin McKittrick3, Robert Harrington4, David Kane5 and Richard Conway6, 1Trinity College Dublin, Dublin 8, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3University of Limerick, Limerick, Ireland, 4St. James's Hospital, Dublin, Dublin, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland, 6Trinity College Dublin, Dublin, Ireland

    Background/Purpose: One of the most significant unmet needs in the management of those with Polymyalgia Rheumatica (PMR)  is the lack of a disease stratification tool…
  • Abstract Number: 1285 • ACR Convergence 2024

    The Impact of Race and Social Determinants of Health on Patient Reported Outcomes in Pediatric Lupus: A CARRA Registry Study

    William Soulsby1, Rebecca Olveda2, Jie He3, Laura Berbert4, Edie Weller3, Kamil Barbour5, Kurt Greenlund5, Laura Schanberg6, Emily Von Scheven1, Aimee Hersh7, Mary Beth Son8, Joyce Chang8 and Andrea Knight9, and the CARRA Registry Investigators, 1University of California, San Francisco, San Francisco, CA, 2Palo Alto Medical Foundation, Dublin, CA, 3Boston Children's Hospital, Boston, MA, 4Boston Children's Hospital, Belmont, MA, 5CDC, Alpharetta, GA, 6Duke University Medical Center, DURHAM, NC, 7University of Utah, Salt Lake City, UT, 8Boston Children's Hospital, Brookline, MA, 9Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Minoritized race and social determinants of health (SDoH) are associated with lower achievement of the low lupus disease activity state (LLDAS) and higher cumulative…
  • Abstract Number: 1467 • ACR Convergence 2024

    Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients with Active Psoriatic Arthritis Treated with Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials

    William Tillett1, Simona Rednic2, Kristi Mizelle3, Christopher Ritchlin4, Saakshi Khattri5, Linyu Shi6, Brenton Bialik6, Thomas Iyile7 and Arthur Kavanaugh8, 1Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, 2Department of Rheumatology, "Iuliu Hațieganu" University of Medicine and Pharmacy and County Emergency Hospital, Cluj-Napoca, Romania, 3Tidewater Physicians Multispecialty Group (TPMG) Rheumatology, Newport News, VA, 4Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 5Mount Sinai Medical Center, New York, NY, 6AbbVie Inc., North Chicago, IL, 7AbbVie Inc., hyattsville, MD, 8University of California San Diego, La Jolla, CA

    Background/Purpose: The phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized double-blind clinical trials demonstrate that risankizumab (RZB) provides a high level of durable improvement in…
  • Abstract Number: 1538 • ACR Convergence 2024

    Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO

    Meenakshi Jolly1, Matt Truman2, Ronald Flauto3 and Kathryn Dao4, 1Rush University, Chicago, IL, 2Aurinia Pharmaceuticals, Victoria, BC, Canada, 3Aurinia Pharmaceuticals, Rockville, MD, 4Rheum101, Rockville, MD

    Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
  • Abstract Number: 2169 • ACR Convergence 2024

    Different Trajectories of Patient Reported Outcomes in Patients with RA in a Stable Phase of Disease – an Observational Study

    Paul Studenic1, Nadine Schwab2, Günther Zauner2, Thi Lan Vi Tran3 and Helga Lechner-Radner4, 1Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria, Vienna, Austria, 2dwh GmbH, simulation services, Vienna, Austria & Institute of Information Systems Engineering, TU Wien, Vienna, Austria, 3Medical University of Vienna, Vienna, Austria, 4Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria

    Background/Purpose: In patients with rheumatoid arthritis (RA), we often see a disconnect between patient and evaluator perceived disease activity. In this study we aim to…
  • Abstract Number: 2359 • ACR Convergence 2024

    A Real-World Study on the Clinical Characteristics and Patient Reported Outcomes of Patients with Active AxSpA Prescribed CT-P13 SC in Five European Countries

    Xenofon Baraliakos1, Ye Eun Lee2, Soyeon Park2, Young Nam Lee2, Megan Hughes3, Molly Edwards3, Emily Quiñones4 and Raj Sengupta5, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 2Celltrion, Inc., Incheon, Republic of Korea, 3Adelphi Real World, Bollington, United Kingdom, 4Adelphi Real World, Macclesfield, United Kingdom, 5Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

    Background/Purpose: CT-P13 SC, a new formulation of infliximab administered subcutaneously, has been approved by European Medicine Agency for the treatment of radiographic axial spondylarthritis (axSpA)…
  • Abstract Number: 2455 • ACR Convergence 2024

    Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)

    Jonathan Li1, Paulina Horvei2, Franziksa Rosser3, Kirsten Rose-Felker4, Vibha Sood5, Adam Olson6, Vickie Vandergrift7, Nicole Hogue2, Lauren Farver8, Devin Mcguire9, Haley Havrilla7, Jessie Alexander10, Shawna McIntyre2, Paul Szabolcs2 and Kathryn Torok11, 1Division of Rheumatology, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 2Division of Blood and Marrow Transplantation and Cellular Therapies, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 3Division of Pulmonology Medicine, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 4Division of Cardiology, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 5Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 6Department of Radiation Oncology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 7Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 8Department of Physical Therapy, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 9Pediatric Behavioral Health, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 10Pediatric Bone Marrow Transplant and Cellular Therapies, Stanford Children's Hospital, Palo Alto, CA, USA, Pittsburgh, 11Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a systemic autoimmune disease characterized by vasculopathy and multiorgan fibrosis leading to significant morbidity and early mortality.  Autologous stem…
  • Abstract Number: 0287 • ACR Convergence 2023

    6-Minute Walk Distance Associates with Physiologic Measures and Physician/Patient Reported Outcomes in Myositis Related Interstitial Lung Disease

    Sangmee Bae1, Fereidoun Abtin2, Grace Kim3, Daniela Markovic4, Siamak Moghadam-Kia5, Chester V. Oddis6, Lila Pourzand2, Didem Saygin6, Daniel Sullivan7, Koichi Yamaguchi8, Donald Tashkin3, Christina Charles-Schoeman9, Jonathan Goldin3 and Rohit Aggarwal6, 1UCLA Rheumatology, Los Angeles, CA, 2UCLA Radiological Sciences, Los Angeles, CA, 3University of California Los Angeles, Los Angeles, CA, 4UCLA Department of Medicine Statistics Core, Los Angeles, CA, 5University of Pittsburgh Medical Center, Pittsburgh, PA, 6University of Pittsburgh, Pittsburgh, PA, 7UCLA Pulmonology, Pittsburgh, PA, 8University of Pittsburgh Medical Center Rheumatology, Pittsburgh, PA, 9UCLA Medical Center, Santa Monica, CA

    Background/Purpose: The 6 minute walk distance (6MWD) provides a global evaluation of sub-maximal exercise capacity that is easily performed and highly reproducible, and is used…
  • Abstract Number: 0414 • ACR Convergence 2023

    Association of a Treat-to-Target Management Approach with Physician and Patient Reported Outcomes Among Real – World Patients with Rheumatoid Arthritis Receiving Advanced Therapy in Europe

    Douglas White1, Aditi Kadakia2, Oliver Howell3, Sander Strengholt4, Emily Goddard3, Sophie Barlow3 and Tsutomu Takeuchi5, 1Waikato Clinical School, University of Auckland, Hamilton, New Zealand, 2AbbVie, Inc., North Chicago, IL, 3Adelphi Real World, Bollington, United Kingdom, 4AbbVie B.V., Mijdrecht, Utrecht, Netherlands, 5Keio University School of Medicine and Saitama Medical University, Tokyo, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease affecting the joints, causing swelling, stiffness, and pain that impact a patient's quality of life. EULAR treatment…
  • Abstract Number: 0488 • ACR Convergence 2023

    Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity

    Nancy Shadick1, Kumiko Schnock2, Vivi Feather3, Ruogu Li2, Jing Cui1, Shivani Patel2, Sabrina Goutier1, Muibat Yussuff2, Lourdes Perez-Chada2, Michael Weinblatt4 and Joseph Merola5, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Mass General Brigham, Boston, MA, 4Harvard Medical School, Waban, MA, 5Harvard Medical School, Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Patients with Psoriatic Arthritis (PsA) and Psoriasis (PsO) have an increased rate of work loss due to their disease compared the general population; however,…
  • Abstract Number: 0754 • ACR Convergence 2023

    Towards a Guide for Evidence-based Remote Monitoring: Sensitivity of Patient Reported Outcomes to Change in Disease Activity Status in Early and Established Rheumatoid Arthritis

    Agnes Loiojen1, Elise van Mulligen2, Annette van der Helm-van Mil3 and Pascal de Jong2, 1Erasmus Medical Center, department of rheumatology, Rotterdam, Netherlands, 2Erasmus Medical Center, Rotterdam, Netherlands, 3Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: In the treatment and follow-up of rheumatoid arthritis (RA) patients, it has become more desirable to detect changes in disease activity through remote monitoring.…
  • 1
  • 2
  • 3
  • …
  • 212
  • Next Page »
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology